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Prognostic value of troponin T in hemodialysis patients is inde- Cardiac troponin T (cTnT) is a sensitive and specific
pendent of comorbidity. marker of myocardial damage [1]. It is used in the diagno-
Background. Patients on long-term hemodialysis have a sis of acute myocardial infarction (AMI) and in the risk-high mortality. Various clinical and biochemical markers are of
stratification of patients with unstable angina pectoris [2].prognostic value. Cardiac troponin T (cTnT) is a sensitive and
Patients on hemodialysis for end-stage chronic renalspecific marker for myocardial damage. Asymptomatic dialysis
patients have a high prevalence of cTnT concentrations above failure have a high mortality, much of it related to cardio-
the diagnostic threshold for myocardial damage. There is con- vascular disease, including AMI. The specificity of cTnT
troversy over whether this represents a false positive cTnT or in the diagnosis of AMI in hemodialysis patients and inan underlying pathology with a poor outcome. It is not known
diabetes has been questioned. The first generation assaywhether cTnT reflects comorbidity in these patients.
for cTnT demonstrated a very high prevalence of positiveMethods. A cohort of 73 long-term hospital hemodialysis pa-
tients had cTnT estimated once prior to a mid-week dialysis. cTnT values in these patients, in the order of 80% [3].
Samples were analyzed using the second-generation cTnT as- Despite the lack of specificity, a positive first generation
say from Boehringer Mannheim on an Elecsys 1010 analyzer.
cTnT has been associated with a poor prognosis in hemo-The standard diagnostic threshold for myocardial damage of
dialysis patients [3]. The second generation assay, utilizing0.1 ng/mL was used. A commonly employed measure of co-
morbidity (Khan) was applied at the time cTnT was measured. two monoclonal antibodies, is more specific for myocardial
Patients were followed for 15 months. Mortality was used as damage. Nevertheless, a proportion of hemodialysis pa-
the clinical end point. Kaplan-Meier survival analysis was em- tients (20 to 50%) remains, with serum cTnT concentra-
ployed and differences between groups were assessed using
tion above the diagnostic cut-off point for myocardialthe Cox-Mantel log-rank test.
damage (0.1 ng/mL) [4 –7]. Several reports have suggestedResults. Of the 73 patients, 20 were positive for cTnT and
53 were negative, at the cut-off of 0.1 ng/mL. At fifteen months, that elevated second generation cTnT is associated with
65% of the positive patients were dead, whereas only 15% of a poor prognosis [5, 8–12]. Other studies have failed to
the negative patients were dead. Survival analysis confirmed detect such an effect [13, 14]. If there is an associationthat this difference was statistically significant (P  0.00001),
between cTnT and prognosis in hemodialysis patients,and that the effect of cTnT on survival was independent of
it remains to be demonstrated that this is independentcomorbidity.
Conclusions. There is a high prevalence of positive cTnT in of the clinical factors that are already known to influence
stable hemodialysis patients. A single estimation of cTnT in survival. These include age, length of time on dialysis, the
this group has significant prognostic value, independent of co- presence of diabetes, ischemic heart disease, left ventric-morbidity.
ular hypertrophy, and other comorbid conditions. Various
clinical scores are used to stratify hemodialysis patients
according to comorbidity [15]. These are used to com-
pare outcomes in dialysis populations. One such scoring
system is that of Khan and co-workers, which has been
shown to correlate with outcome (Table 1) [16]. If cTnT
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is of prognostic value in hemodialysis patients, the opti-disease, ischemic heart disease, peripheral vascular disease, acute myo-
cardial infarction. mal cut-off point (diagnostic threshold) of serum cTnT
concentration remains to be established.Received for publication February 21, 2001
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Table 2. Patient demographicsTable 1. Comorbidity scoring systema
Risk group Inclusion criteria Characteristic
Sex ratio male : female 42 :31Low Age 70 years and no comorbid illness
Diabetes N12Medium Age 70–80 years
Peripheral vascular disease N23or
Ischemic heart disease N18Age 80 years with any one of the following:
Age years, range; median (SD) 23–91, 64 (18)angina, previous myocardial infarction, cardiac
Length of time on RRT months, range 1–120failure, chronic obstructive airways disease, pul-
monary fibrosis, liver disease (cirrhosis, chronic
hepatitis)
High Age 80 years
or Analytical methods
Any age with two or more organ dysfunctions in addi-
Cardiac troponin T was estimated using the second-tion to end-stage renal disease
or generation Elecsys Troponin T STAT immunoassay from
Any age with diabetes or cardiopulmonary disease Boehringer Mannheim, on the Elecsys 1010 immunoassay
or
analyzer. The detection limit of the assay is 0.01 ng/mL.Any age with visceral malignancy
The coefficient of inter-assay analytical variation in oura This clinical prognostic scoring system was developed by Khan et al [16]
hands, at the cut-off point of 0.1 ng/mL, was6%. Urea
reduction ratio (URR) was calculated as the difference
between the serum urea concentration pre- and post-
dialysis, divided by the serum urea pre-dialysis.prognostic index. A further aim of the study was to deter-
mine the optimal prognostic cut-off concentration of cTnT.
Statistical methods
Kaplan-Meier survival analysis was performed. Differ-
METHODS ences in survival between groups were analyzed using
Study design the Cox-Mantel log rank test. The Cox regression model
was used to compare the predictive value of cTnT and theSurvival of a group of 73 patients on long-term hospi-
clinical scoring system. Receiver operating characteristictal hemodialysis was examined. The total hospital popu-
(ROC) curve analysis was used to determine the cut-offlation of chronic hospital hemodialysis patients was 81.
point that maximized both sensitivity and specificity. TheBlood samples suitable for the analysis of cTnT were
diagnostic efficiency (true positives plus true negatives,available for 73 patients. Each patient had cTnT esti-
divided by total number of tests) of the test at differentmated once. cTnT estimation was completed for all pa-
cut-off points was plotted to determine the cut-off pointtients within a three-day period. This study used the
that correctly assigned the greatest number of patients.standard laboratory cut-off point for the diagnosis of
myocardial damage of 0.1 ng/mL. Patients were followed Patients
up for 15 months. Clinical details were obtained at the
Patient characteristics are shown in Table 2.
end of the period by review of clinical notes by a nephrol-
There was a broad range of ages and lengths of time on
ogist familiar with the patients, but unaware of the cTnT renal replacement therapy (RRT). There was a male
results. The patients were categorized according to the predominance.
clinical prognostic scoring system of Khan and co-work-
ers [16], applied at the time at which the sample was
RESULTStaken for cTnT (Table 1). A subgroup analysis was per-
formed of patients who were expected to have a higher Distribution of cTnT
prevalence of cTnT. These included 12 patients with Twenty patients out of seventy-three had serum cTnT
diabetes, 18 patients with symptomatic ischemic heart greater than 0.1 ng/mL. The distribution of cTnT results
disease (IHD) and 23 patients with known peripheral is shown in Figure 1. There was no significant correlation
vascular disease (PVD). between cTnT and urea reduction ratio (r  0.1033,
Echocardiograms were performed as part of routine P  0.4).
clinical care in 57 of the patients and were performed by
Outcomea number of different technicians. Data was extracted
from the clinical notes and by searching the echocardi- After 15 months of follow-up, 21 patients had died,
ography database. Assessment of left ventricular hyper- leaving 52 survivors. The prevalence of cTnT greater than,
trophy (LVH) and of left ventricular systolic function and less than, the cut-off point of 0.1 ng/mL and their
(LVSF) was based on the interpretation of the cardiolo- respective survival to 15 months is shown in Table 3.
Prevalence of positive cTnT and survival in the followinggist reporting the echocardiogram.
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Cox regression model
The Cox regression model was used to compare the
predictive value of the comorbidity score and cTnT as
binary variables, described above. It demonstrated that
both variables were significant independent predictors
of mortality and that the hazard ratio associated with
a high risk comorbidity score was 6.7 (compared with
medium and low risk combined), and the hazard ratio
associated with a positive cTnT (compared with a nega-
tive cTnT) was 4.1.
Cause of death
Cause of death was established in the twenty-one who
Fig. 1. Frequency histogram of cardiac troponin T (cTnT) concentra-
died, by review of clinical notes. There was no evidencetion in 73 hemodialysis patients.
of any tendency for cTnT positive patients to have a
cardiac, as opposed to a non-cardiac death. Classified
as cardiac were the following deaths: two myocardial
patient groups is also shown in the Table 3: patients in the infarctions, six cardiac arrests and four cases of cardiac
low-, medium- and high-risk groups, diabetic patients, failure. Classified as non-cardiac were the following
deaths: four withdrawals from dialysis treatment as apatients with symptomatic ischemic heart disease and
result of severe intractable comorbidity, four cases ofpatients with known peripheral vascular disease. In each
sepsis and one malignancy. The distribution of cTnTsubgroup those with a negative cTnT had a better out-
among the cardiac and non-cardiac causes of death iscome. The distribution of cTnT and of survival within
shown in Table 5.groups, divided according to echocardiographic findings,
is shown in Table 4. Within the group with left ventricular
Determination of cut-off pointshypertrophy (LVH) and within the group of patients
The receiver operating characteristic (ROC) curve forwith good left ventricular systolic function (LVSF), a
cTnT as a predictor of death at 15 months is shown in Fig-positive cTnT was a marker of poor outcome. Patients
ure 6. The area under the ROC curve was 0.857, standardwith impaired left ventricular systolic function had a very
error 0.055, 95% confidence interval 0.755 to 0.928. Thepoor prognosis irrespective of cTnT.
point at which sensitivity and specificity were equal (at
76%) was at cTnT concentration of 0.063 ng/mL.Survival analysis
In terms of diagnostic efficiency, the proportion of pa-The Kaplan-Meier survival curve of the 73 patients,
tients correctly assigned (true positives plus true negativesdivided into those who were cTnT positive and negative
divided by total), there was essentially no difference be-is shown in Figure 2. The difference in survival was
tween cut-off points between 0.06 and 0.2 ng/mL (Fig. 7).statistically significant (P  0.00001, Cox-Mantel log-
The Cox regression model was repeated to assess whe-rank test). The survival curve of the 73 patients divided
ther the 0.06 ng/mL cut-off point performed better thanaccording to the comorbidity score into three groups
the 0.1 ng/mL cut-off point. This demonstrated that when
(low, medium and high risk) is shown in Figure 3. The
using the 0.06 ng/mL cut-off point, the hazard ratio asso-
difference in survival between the groups was statistically
ciated with a positive cTnT was 4.8, while the hazard ratio
significant (P  0.0001, Cox-Mantel log-rank test). associated with a high risk score was reduced to 4.3.
To make a valid comparison between cTnT and co-
morbidity as predictors of mortality, we expressed both
DISCUSSIONindices as binary variables (cTnT positive versus cTnT
negative: High-risk versus medium- and low-risk groups The high prevalence of raised cTnT in asymptomatic
combined). Kaplan-Meier survival analysis was performed dialysis patients undermines the role of this marker in
for the 43 patients in the combined low and medium risk the diagnosis of acute coronary syndromes in this group
groups, and is shown in Figure 4. The number of events in of patients. Cardiac troponin I has been shown to be a
the low risk group was too low to allow survival analysis better predictor of acute myocardial damage than tropo-
according to cTnT status. The survival analysis for the 30 nin T, in dialysis patients who present with chest pain
high risk patients is shown in Figure 5. In both subgroups [17]. Van Lente and co-workers found that in a group
cTnT was a significant predictor of mortality (P  0.001 of renal patients (only 9% of whom were dialysis-depen-
dent) who presented with chest pain, both cTnT and TnIand P  0.05, respectively).
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Table 3. Prevalence of cTnT above and below the cut-off point in 73 hemodialysis patients and in sub-groups of those patients,
and their respective survival to 15 months
Number Survival %
cTnT cTnT cTnT cTnT
Group Total 0.1 ng/mL 0.1 ng/mL Total 0.1 ng/mL 0.1 ng/mL
All 73 20 53 71 35 85
Low risk 21 1 20 100 100 100
Medium risk 22 6 16 82 50 94
High risk 30 13 17 43 23 59
Diabetes 12 7 5 50 29 80
IHD 18 8 10 61 25 90
PVD 23 13 10 48 31 70
Abbreviations are: cTnT, cardiac troponin T; IHD, ischemic heart disease; PVD, peripheral vascular disease.
Table 4. Prevalence of left ventricular hypertrophy (LVH) and left ventricular systolic function (LVSF) in 73 hemodialysis patients,
cTnT above and below the cut-off point in these groups, and their respective survival to 15 months
Number Survival %
cTnT cTnT cTnT cTnT
Group Total 0.1 ng/mL 0.1 ng/mL Total 0.1 ng/mL 0.1 ng/mL
LVH 31 11 20 52 9 75
No LVH 11 2 9 91 50 100
No LVH data 31 7 24 84 71 88
Poor LVSF 11 7 4 45 43 50
Good LVSF 44 11 33 70 18 88
No LVSF data 18 2 16 89 100 88
Fig. 2. Kaplan-Meier survival curve of 73 hemodialysis patients ac- Fig. 3. Kaplan-Meier survival curve of 73 hemodialysis patients ac-
cording to cardiac troponin T concentration. cording to Khan comorbidity score.
predicted adverse outcomes less well than in non-renal appropriate to compare the prognostic value of cTnT
patients [18].
with comorbidity at the same time.
We have demonstrated that a single estimation of
Use of the Cox regression model in our study was lim-cTnT is a predictor of mortality in chronic hemodialysis
ited to estimating the relative strength of cTnT and thepatients, independent of a commonly used clinical prog-
clinical comorbidity score in predicting death in dialysisnostic index. Khan and co-workers used their clinical
patients. We did not seek to determine the best model toscore at the start of dialysis. We modified the use of
predict death in these patients, and thus no other bio-the comorbidity score by applying it at the time of the
chemical and clinical factors were included in the model.estimation of cTnT. Since cTnT was measured at a single
Patients were grouped so that both the clinical score andtime point, which for these patients was at varying stages
in the natural history of their disease, we believed it was cTnT status would be in a binary format, so that like
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Fig. 4. Kaplan-Meier survival curve of 43 low- and medium-risk hemo-
dialysis patients according to cardiac troponin T concentration.
Fig. 6. Receiver operating characteristic (ROC) curve for cardiac tro-
ponin T concentration as a predictor of death at 15 months in 73
hemodialysis patients.
Fig. 5. Kaplan-Meier survival curve of 30 high-risk hemodialysis pa-
tients according to cardiac troponin T concentration.
Table 5. Cause of death and cardiac troponin T status among
the 21 patients who died
cTnT cTnT
Cause 0.1 ng/mL 0.1 ng/mL Total
Cardiac 7 5 12
Non-cardiac 6 3 9
Total 13 7 21 Fig. 7. Diagnostic efficiency of cardiac troponin T as a predictor of
death at 15 months, as a function of cardiac troponin T concentration.
could be compared with like, as well as to express the
A further study, which demonstrated that cTnT hadoutcome of the analysis in the form of hazard ratios.
no effect on prognosis in chronic renal failure, examinedPrevious studies have shown that cTnT is a predictor
a diverse group of patients and included only 20 hemodi-of mortality in dialysis patients, independent of certain
alysis patients [13]. Mockel et al excluded patients withselected single diagnoses, such as diabetes or vascular
symptoms of ischemic heart disease, thus selecting a low-disease [8, 11, 19]. Those authors did not evaluate
risk population. In our study, the patients in the lowestwhether cTnT contributed prognostic information in ad-
risk group had a very favorable prognosis and a lowdition to what was obtained from recognized clinical
prevalence of positive cTnT concentration, making itprognostic indices. The cTnT testing protocol in the first
difficult to assess whether a negative cTnT confers aof these studies was different to ours. Those authors
survival advantage in this group with the lowest riskmeasured cTnT on three occasions and used the highest
score. We noted that patients with a history of ischemicconcentration, and thus had a higher prevalence of posi-
tive patients. heart disease, but without recent symptoms suggestive
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of an acute coronary syndrome, who were negative for lar association between cardiac Troponin T and fatal
cardiovascular events was found by Dierkes and co-cTnT, had a good prognosis. We believe that these pa-
tients should be included in studies into the prognostic workers [19].
In our study, however, there did not appear to be avalue of cTnT in dialysis patients.
This study demonstrated that the cut-off point of relative excess of cardiac, as opposed to non-cardiac,
death among the cTnT positive patients. The cause of0.1 ng/mL, as is used in the risk stratification of unstable
angina, is a reasonable cut-off point for predicting out- death was determined by review of case notes and no
post-mortem examinations were performed. Sudden, un-come in hemodialysis patients. This cut-off point is close
to the point on the ROC curve where sensitivity and expected death at home, one of the principal modes of
death in these patients, was classified as cardiac arrest.specificity are maximal. It also falls within the range
in which good diagnostic efficiency is obtained. Larger This relatively crude and limited analysis should not be
expected to correlate closely with detailed post-mortemstudies may be required to define the cut-off point with
the greatest diagnostic efficiency more precisely. The examinations.
The discrepancy between the prevalence of positivefinding that diagnostic efficiency is maximal at a higher
cut-off point than that determined by ROC curve analy- cTnT and cTnI in dialysis patients has been debated [21].
It is known that cTnI has a shorter serum half-life. Itsis is a reflection of the fact that survival was, overall, a
more likely outcome than death in this group. Thus, one also is known that the two epitopes on the cTnT molecule
that are recognized by the current cTnT assay are verywas more likely to be correct if one predicted survival
rather than death. Choosing a higher cut-off point is the close together and thus make the assay quite resistant
to instability on storage. Cleavage of the molecule mustequivalent of predicting more survivors. Unlike analysis
of diagnostic efficiency, ROC curve analysis, by empha- occur between the two epitopes for the molecule to fail
to react in the assay system. The epitopes recognized bysizing sensitivity and specificity, does not take into ac-
count the prevalence of the outcome in question. most of the various cTnI assay systems are situated fur-
ther apart on the molecule. Thus, proteolytic degrada-The fact that the 0.06 ng/mL cut-off point emerged as
a better predictor using the Cox model suggests that tion products of cTnT are much more likely to be de-
tected by the cTnT assay than are cTnI degradationthe prognostic information provided by cTnT at lower
concentrations is more independent of clinical markers products in the cTnI assay systems. Wu and co-workers
speculate that retention of proteolytic degradation prod-of comorbidity than at higher cTnT concentrations. If
one is interested in using cTnT as an additional factor ucts of cTnT in dialysis patients, which are detected by
the cTnT assay, may make the cTnT assay more sensitivein a panel of clinical and biochemical markers of progno-
sis (and if one chooses to express cTnT as a binary vari- to minor degrees of myocardial damage [23]. Thus, they
suggest that the signal caused by minor ongoing myocar-able), then the 0.06 ng/mL cut-off point would be prefer-
able to the 0.1 ng/mL cut-off point as it contributes more dial damage is amplified in the case of cTnT in dialysis
patients, but not in the case of cTnI.independent information.
The biological process underlying the increased cTnT Predicting survival in renal dialysis patients is impor-
tant. When comparing clinical outcomes between differ-in hemodialysis patients is unclear. Several hypotheses
have been proposed. It has been suggested that the skele- ent renal units, as part of benchmarking exercises, it is
essential to correct for the underlying comorbidity andtal myopathy associated with end-stage renal failure in-
duces expression of the fetal isoform, which happens to for the prognosis of the patients [16]. Clinical prognostic
factors have been thoroughly explored. Biochemical prog-be cTnT, in replicating skeletal muscle, and that this gives
rise to the false-positive cTnT result. This hypothesis has nostic factors such as C-reactive protein may add to the
ability to predict outcome [24]. cTnT may, in the future,been disputed [20, 21]. It also has been suggested that the
presence of left ventricular hypertrophy, silent ischemia, be included in a panel of biochemical markers used to
assist in this process. The concept of rationing dialysis onand metabolic cardiomyopathy may cause this elevation
of cTnT in dialysis patients. In a diverse group of patients the basis of prognosis has been opened for debate [15].
Other treatment options may also be considered in thewho underwent post-mortem examination and who in-
cluded a small number of dialysis patients, antemortem light of a patient’s prognosis, such as referral for revascu-
larization procedures or renal transplantation. In ourcTnT was associated with a range of abnormal myocar-
dial histologic findings [22]. The independent association study, dialysis patients with left ventricular hypertrophy
(LVH) who had a positive cardiac Troponin T had abetween cTnT and death in hemodialysis patients would
seem to favor a cardiac pathology. Ooi et al [11], in much worse prognosis than similar patients with negative
cTnT. This difference suggests that it might be possiblecontrast with their findings at twelve months of follow-
up, found that follow-up at thirty-six months demon- target therapy aimed at inducing regression of LVH at
those patients with the poorest prognosis, that is, thosestrated that a positive cardiac Troponin T was associated
with cardiac—as opposed to non-cardiac—death. A simi- with a positive cTnT.
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